Out-of-pocket cost of naloxone may keep many uninsured from using life-saving treatment
The cost of buying the opioid antidote naloxone is out of reach for many uninsured Americans, a hurdle that may keep the treatment from saving more people who overdose on opioids, according to a new RAND Corporation study.
Aug 19, 2022
0
60